Combined IL-21-primed polyclonal CTL plus CTLA4 blockade controls refractory metastatic melanoma in a patient

Adoptive transfer of peripheral blood-derived, melanoma-reactive CD8(+) cytotoxic T lymphocytes (CTLs) alone is generally insufficient to eliminate bulky tumors. Similarly, monotherapy with anti-CTLA4 infrequently yields sustained remissions in patients with metastatic melanoma. We postulated that a...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:The Journal of experimental medicine Ročník 213; číslo 7; s. 1133
Hlavní autori: Chapuis, Aude G, Lee, Sylvia M, Thompson, John A, Roberts, Ilana M, Margolin, Kim A, Bhatia, Shailender, Sloan, Heather L, Lai, Ivy, Wagener, Felecia, Shibuya, Kendall, Cao, Jianhong, Wolchok, Jedd D, Greenberg, Philip D, Yee, Cassian
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: United States 27.06.2016
Predmet:
Adoptive Transfer - methods
CD8-Positive T-Lymphocytes - transplantation
CTLA-4 Antigen - immunology
Female
Humans
Interleukins - immunology
Male
Melanoma - immunology
Melanoma - therapy
Middle Aged
Neoplasm Metastasis
ISSN:1540-9538, 1540-9538
On-line prístup:Zistit podrobnosti o prístupe
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Popis
Shrnutí:Adoptive transfer of peripheral blood-derived, melanoma-reactive CD8(+) cytotoxic T lymphocytes (CTLs) alone is generally insufficient to eliminate bulky tumors. Similarly, monotherapy with anti-CTLA4 infrequently yields sustained remissions in patients with metastatic melanoma. We postulated that a bolus of enhanced IL-21-primed polyclonal antigen-specific CTL combined with CTLA4 blockade might boost antitumor efficacy. In this first-in-human case study, the combination successfully led to a durable complete remission (CR) in a patient whose disease was refractory to both monoclonal CTL and anti-CTLA4. Long-term persistence and sustained anti-tumor activity of transferred CTL, as well as responses to nontargeted antigens, confirmed mutually beneficial effects of the combined treatment. In this first-in-human study, Chapuis et al. demonstrate that the combination of adoptive cellular therapy with CTLA4 blockade induces long-term remission in a melanoma patient resistant to both modalities administered serially and individually.
Bibliografia:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ISSN:1540-9538
1540-9538
DOI:10.1084/jem.20152021